Ppar Articles

Single, dual and pan-PPAR agonists are under development for the pharmacological treatment of NASH, ? read more from our articles.

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Advanced chronic liver disease (ACLD) is a serious public health issue for which a safe and effective treatment is still lacking. It is often associated with portal hypertension and liver fibrosis. Over the recent years, peroxisome proliferator-activated receptors family (PPARs) have been considered as a relevant...
Read MorePan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

PPARs and immune responses

Peroxisome proliferator-activated receptors (PPARs) are fatty acid-activated transcription factors of nuclear hormone receptor superfamily that regulate energy metabolism. Currently, three PPAR subtypes have been identified: PPARα, PPARγ, and PPARβ/δ. PPARα and PPARδ are highly expressed in oxidative tissues and regulate genes involved in substrate delivery...
Read MorePPARs and immune responses

Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease

anifibranor is a moderately potent and well-balanced modulator of the three PPAR isotypes and has a good safety profile. Beneficial effects of lanifibranor on NASH histology, including reduced fibrosis, were confirmed recently in a preclinical model of NASH and fibrosis (choline-deficient amino acid-defined HFD mouse model)...
Read MorePeroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease

Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis, S. Lefere et al. studied the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. To examine the pathophysiological sequence of steatohepatitis...
Read MoreExperimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

In an experimental study, S. Lefere et al. investigated the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. The authors employed the CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis...
Read MoreDifferential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH...

Read MoreHuman hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.